title: [Protective effect of ulinastatin on pulmonary function after cardiopulmonary bypass].
abstract: OBJECTIVE
  To investigate the effects of Ulinastatin with different doses on pulmonary protection after cardiopulmonary bypass (CPB).
  
  
  METHODS
  Ninety patients after CPB were brought into this study and divided into low doses Ulinastatin group (L group, n=30, 5 000 U/kg), high doses Ulinastatin group (H group, n=30, 20 000 U/kg) and control group (C group, n= 30), respectively. When the patients were transferred into ICU after CPB, Ulinastatin was given intravenously to those in L and H group, while saline was given in C group. Blood samples were harvested at the time before the treatments (T0) and 12 hours (T1), 24 hours (T2) after the treatments, for the measurements of arterial pressure of oxygen (PaO2), arterial pressure of carbon monoxide (PaCO2),difference of alveoli-arterial oxygen pressure (PO(2A), oxygenation index (Ol),and tumor necrosis factor-alpha (TNF-alpha) level. Pulmonary dynamic compliance (Cd), plat pressure (Pplat) and peak pressure (Ppeak) were determined at the time of To and wean (Tw). The durations of ventilation and intubation were recorded.
  
  
  RESULTS
  At T0, the levels of PaO2, PaCO2, PO2A-a, OI and TNF-alpha in each group showed no significantly difference (P> 0. 05). At T1 and T2, the patients in H group had higher levels of PO2, PO2A-a. and OI, lower level of TNF-alpha, shorter duration of ventilation and intubation than the patients in other two groups(P<0. 05). The parameters in L group were better than those in C group, but the differences were not stastically significant (P>0. 05). There was no significantly difference in the levels of Cd, Pplat, and Ppeak at T0 and Tw between any two groups (P>0. 05). The intubation and ventilation time in H group were shorter than that in L and C group (P<0. 05).
  
  
  CONCLUSIONS
  The application of Ulinastatin could achieve pulmonary protective effect after CPB, and it seems the effect could be better with high dose (20 000 U/kg) of Ulinastatin.
authors: Department of ICU, Guizhou Province People's Hospital,Guiyang 550002, China.
authors: Xian-qing
authors: XQ
authors: Shi
authors: Yu-Hui
authors: YH
authors: Wang
authors: Jian-Quan
authors: JQ
authors: Li
authors: Yuan-Dong
authors: YD
authors: Hu
authors: Xiao-Rong
authors: XR
authors: Cheng
authors: Kun
authors: K
authors: Li
mesh_terms: D055371:Acute Lung Injury / Q000209:etiology / Q000517:prevention & control*; D000328:Adult; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D020011:Protective Agents / Q000008:administration & dosage; D012129:Respiratory Function Tests; D014361:Trypsin Inhibitors / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D006023:Glycoproteins; D020011:Protective Agents; D014361:Trypsin Inhibitors; C028665:urinastatin